Research Article 
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer‘s Association Research Roundtable Workgroup
Reisa A. Sperling, Clifford R. Jack, Sandra E. Black, Matthew P. Frosch, Steven M. Greenberg, Bradley T. Hyman, Philip Scheltens, Maria C. Carrillo, William Thies, Martin M. Bednar, Ronald S. Black, H. Robert Brashear, Michael Grundman, Eric R. Siemers, Howard H. Feldman and Rachel J. Schindler
Alzheimer`s & Dementia, 2011, 7(4), 367-385. DOI: 10.1016/j.jalz.2011.05.2351
Abstract
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in Alzheimer‘s disease (AD). In response to concerns raised by the Food and Drug Administration, the Alzheimer‘s Association Research Roundtable convened a working group to review the publicly available trial data, attempts at developing animal models, and the literature on the natural history and pathology of related conditions. The spectrum of ARIA includes signal hyperintensities on fluid attenuation inversion recoverysequences thought to represent ”vasogenic edema“ and/or sulcal effusion (ARIA-E), as well as signal hypointensities on GRE/T2∗ thought to represent hemosiderin deposits (ARIA-H), including microhemorrhage and superficial siderosis. The etiology of ARIA remains unclear but the prevailing data support vascular amyloid as a common pathophysiological mechanism leading to increased vascular permeability. The workgroup proposes recommendations for the detection and monitoring of ARIA in ongoing AD clinical trials, as well as directions for future research.
ASCI-ID: 285-146
Similar Articles
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans
Alzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnosesAlzheimer`s & Dementia, 2010, 6(2), 104-109. DOI: 10.1016/j.jalz.2009.12.005
Anesthesia in presymptomatic Alzheimer‘s disease: A study using the triple-transgenic mouse modelAlzheimer`s & Dementia, 2011, 7(5), 521-531. DOI: 10.1016/j.jalz.2010.10.003
Dementia and Alzheimer‘s disease: A new direction. The 2010 Jay L. Foster Memorial LectureAlzheimer`s & Dementia, 2011, 7(5), 540-550. DOI: 10.1016/j.jalz.2011.05.901
Effect of human cerebrospinal fluid sampling frequency on amyloid-β levelsAlzheimer`s & Dementia, 2012, 8(4), 295-303. DOI: 10.1016/j.jalz.2011.05.900
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Cerebral atrophy, apolipoprotein E ε4, and rate of decline in everyday function among patients with amnestic mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 404-411. DOI: 10.1016/j.jalz.2010.02.003
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Magnetic resonance imaging-measured atrophy and its relationship to cognitive functioning in vascular dementia and Alzheimer‘s disease patientsAlzheimer`s & Dementia, 2011, 7(5), 493-500. DOI: 10.1016/j.jalz.2011.01.004
Impact of apolipoprotein ɛ4–cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairmentAlzheimer`s & Dementia, 2011, 7(5), 514-520. DOI: 10.1016/j.jalz.2010.12.010
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's diseaseAlzheimer`s & Dementia, 2012, 8(1), 51-59. DOI: 10.1016/j.jalz.2011.06.003
An investigation of PreMCI: Subtypes and longitudinal outcomesAlzheimer`s & Dementia, 2012, 8(3), 172-179. DOI: 10.1016/j.jalz.2011.03.002
Vascular risk factors, apolipoprotein E, and hippocampal decline on magnetic resonance imaging over a 10-year follow-upAlzheimer`s & Dementia, 2012, 8(5), 417-425. DOI: 10.1016/j.jalz.2011.07.005
Greater regional brain atrophy rate in healthy elderly subjects with a history of cigarette smokingAlzheimer`s & Dementia, 2012, 8(6), 513-519. DOI: 10.1016/j.jalz.2011.10.006
Decreased gray matter diffusivity: A potential early Alzheimer‘s disease biomarker?Alzheimer`s & Dementia, 2013, 9(1), 93-97. DOI: 10.1016/j.jalz.2011.11.004
Amyloid positron emission tomography with 18F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer‘s diseaseAlzheimer`s & Dementia, 2013, 9(3), 295-301. DOI: 10.1016/j.jalz.2012.01.006
Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumabAlzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353